Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma

CONCLUSIONS: These results establish LP-184 as a promising chemotherapeutic for GBM with enhanced efficacy in intrinsic or spironolactone-induced TC-NER deficient tumors.PMID:37494541 | DOI:10.1158/1078-0432.CCR-23-0673

Source: Cell Research - July 26, 2023 Category: Cytology Authors: Bachchu Lal Aditya Kulkarni Joseph McDermott Rana Rais Jesse Alt Ying Wu Hernando Lopez-Bertoni Sophie Sall Umesh Kathad Jianli Zhou Barbara S Slusher Kishor Bhatia John Laterra Source Type: research